| Literature DB >> 30424781 |
Clarer Jones1, Billy Ngasala2,3, Yahya A Derua4, Donath Tarimo2, Lisa Reimer5, Moses Bockarie6, Mwelecele N Malecela7.
Abstract
BACKGROUND: Control of lymphatic filariasis (LF) in most of the sub-Saharan African countries is based on annual mass drug administration (MDA) using a combination of ivermectin and albendazole. Monitoring the impact of this intervention is crucial for measuring the success of the LF elimination programmes. This study assessed the status of LF infection in Rufiji district, southeastern Tanzania after twelve rounds of MDA.Entities:
Keywords: Circulating filarial antigens; Elephantiasis; Hydrocele; Lymphatic filariasis; Mass drug administration; Microfilaremia; Tanzania; Wuchereria bancrofti
Mesh:
Substances:
Year: 2018 PMID: 30424781 PMCID: PMC6234578 DOI: 10.1186/s13071-018-3156-2
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Reported treatment coverage during ivermectin and albendazole MDA intervention in Rufiji District, southeastern Tanzania
| MDA No. | Treatment year | Target population | Treated population (% coverage) |
|---|---|---|---|
| 1 | 2002 | 138,370 | 75,135 (54.3) |
| 2 | 2003 | 141,628 | 123,216 (87.0) |
| 3 | 2004 | 144,962 | 136,267 (94.0) |
| 2005a | – | – | |
| 4 | 2006 | 151,868 | 85,046 (56.0) |
| 5 | 2007 | 155,443 | 116,583 (75.0) |
| 6 | 2008 | 159,103 | 115,350 (72.5) |
| 7 | 2009 | 162,848 | 130,279 (80.0) |
| 8 | 2010 | 166,682 | 113,677 (68.2) |
| 9 | 2011 | 170,606 | 150,133 (88.0) |
| 10 | 2012 | 236,614 | 146,060 (61.7) |
| 11 | 2013 | 243,835 | 149,163 (61.2) |
| 12 | 2014 | 217,274 | 168,930 (77.7) |
aMDA was not implemented in 2005
Prevalence of CFA, microfilariae and clinical manifestation of lymphatic filariasis infection by gender, age and village location in Rufiji District, southeastern Tanzania
| Characteristic | No. (%) examined | No. (%) with CFA [95% CI] | No. (%) with MF [95% CI] | No. (%) with hydrocelea | No. (%) with elephantiasis |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 481 (56.3) | 8 (1.7) [0.8–3.2] | 1 (0.2) [0.0–1.2] | 23 (4.8) | 18 (3.7) |
| Female | 373 (43.7) | 1 (0.3) [0.1–1.5] | 0 (0.0) [0.0–1.0] | – | 7 (1.9) |
| Total | 854 | 9 (1.1) [0.6–2.0] | 1 (0.1) [0.0–0.7] | 23 (4.8) | 25 (2.9) |
| Age (years) | |||||
| 5–14 | 188 (22.1) | 1 (0.5) [0.1–3.0] | 0 (0.0) [0.0–2.0] | 0 (0.0) | 1 (1.0) |
| 15–34 | 307 (35.9) | 4 (1.3) [0.5–3.3] | 1 (0.3) [0.1–1.8] | 8 (4.7) | 13 (7.8) |
| ≥ 35 | 359 (42.0) | 4 (1.1) [0.4–2.8] | 0 (0.0) [0.0–1.1] | 15 (7.0) | 11 (5.2) |
| Total | 854 | 9 (1.1) [0.6–2.0] | 1 (0.1) [0.0–0.7] | 23 (4.8) | 25 (2.9) |
| Village | |||||
| Nyamisati | 213 (24.9) | 0 (0.0) [0.0–1.8] | 0 (0.0) [0.0–1.8] | 7 (4.1) | 5 (2.3) |
| Nyambili | 196 (23.0) | 6 (3.1) [1.4–6.5] | 1 (0.5) [0.1–2.8] | 5 (5.0) | 10 (5.1) |
| Nyanjati | 189 (22.1) | 0 (0.0) [0.0–2.0] | 0 (0.0) [0.0–2.0] | 3 (3.6) | 7 (4.1) |
| Bungu | 172 (20.1) | 3 (1.7) [0.6–5.0] | 0 (0.0) [0.0–2.2] | 4 (5.1) | 3 (1.7) |
| Mchukwi | 84 (9.8) | 0 (0.0) [0.0–4.4] | 0 (0.0) [0.0–4.4] | 4 (8.3) | 0 (0.0) |
| Total | 854 | 9 (1.1) [0.6–2.0] | 1 (0.1) [0.0–0.7] | 23 (4.8) | 25 (2.9) |
aDenominator included only males
Filarial mosquito vectors caught and analyzed for infection and or/infectivity with W. bancrofti using microscopy and qPCR
| Collection method | Vector collected | Parous vectors | Method of analysis | No. analyzed | No. infected (%) | No. infective (%) |
|---|---|---|---|---|---|---|
| Light trap | 1123a | 558b | Microscopy | 558 | 0 (0) | 0 (0) |
| Gravid trap | 5460 | – | qPCR | 1092c | 5 (0.1)d | 0 (0) |
aFilarial vector composition: Anopheles gambiae complex (n = 69) and Culex quinquefasciatus (n = 1054)
bParous vectors: An. gambiae complex (n = 45) and Cx. quinquefasciatus (n = 513)
cPools of 5 Cx. quinquefasciatus each
dInfection rate (Pool Screen V2.0.2; Likelihood ratio method; 95% CI: 0.03–0.22%)
Demographic characteristics of the study population and their reported drug uptake in relation to their LF infection status
| Characteristic | No. (%) of total | No. (%) with CFA | No (%)a with hydrocele | No (%) with elephantiasis | |||
|---|---|---|---|---|---|---|---|
| Gender ( | |||||||
| Males | 481 (56.3) | 8 (1.6) | 3.921 (0.048) | 23 (4.8) | – | 18 (3.7) | 2.573 (0.109) |
| Females | 373 (43.7) | 1 (0.3) | 7 ( 1.9) | ||||
| Age groups in years ( | |||||||
| ≤ 29 | 450 (52.7) | 4 (0.9) | 0.248 (0.618) | 5 (2.0) | 8.723 (0.003) | 13 (2.9) | 0.005 (0.944) |
| ≥ 30 | 404 (47.3) | 5 (1.2) | 18 (7.8) | 12 (3.0) | |||
| Reported drug uptake in previous MDAs ( | |||||||
| Yes | 704 (82.4) | 4 (0.6) | 8.723 (0.003) | 9 (2.4) | 22.743 (0.001) | 19 (2.7) | 0.737 (0.391) |
| No | 150 (17.6) | 5 (3.3) | 14 (13.7) | 6 (4.0) | |||
| Reported drug uptake in 2014 MDA ( | |||||||
| Yes | 603 (70.6) | 6 (1.0) | 0.068 (0.794) | 8 (2.5) | 10.243 (0.001) | 16 (2.7) | 0.542 (0.462) |
| No | 251 (29.4) | 3 (1.2) | 15 (9.1) | 9 (3.6) | |||
aDenominator included only males: for age group ≤ 29 and ≥ 30 there were 249 and 232 males; drug uptake in any previous MDA, 379 males swallowed the drugs while 102 did not swallow the drugs; drug uptake in 2014 MDA, 316 males swallowed the drugs while 165 did not